{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T08:48:50Z","timestamp":1777970930946,"version":"3.51.4"},"reference-count":103,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1080\/13543776.2024.2446228","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T11:13:24Z","timestamp":1735298004000},"page":"111-136","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Small molecule ATM inhibitors as potential cancer therapy: a patent review (2003\u2013present)"],"prefix":"10.1080","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8968-0879","authenticated-orcid":false,"given":"Yan A.","family":"Ivanenkov","sequence":"first","affiliation":[{"name":"P. Hertsen Moscow Oncology Research Institute","place":["Moscow, Russian Federation"]},{"name":"The Federal State Unitary Enterprise Dukhov Automatics Research Institute","place":["Moscow, Russian Federation"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5308-1698","authenticated-orcid":false,"given":"Alexander S.","family":"Malyshev","sequence":"additional","affiliation":[{"name":"P. Hertsen Moscow Oncology Research Institute","place":["Moscow, Russian Federation"]},{"name":"The Federal State Unitary Enterprise Dukhov Automatics Research Institute","place":["Moscow, Russian Federation"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7799-9383","authenticated-orcid":false,"given":"Victor A.","family":"Terentiev","sequence":"additional","affiliation":[{"name":"P. Hertsen Moscow Oncology Research Institute","place":["Moscow, Russian Federation"]},{"name":"The Federal State Unitary Enterprise Dukhov Automatics Research Institute","place":["Moscow, Russian Federation"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8061-8754","authenticated-orcid":false,"given":"Anastasia A.","family":"Korzhenevskaya","sequence":"additional","affiliation":[{"name":"Peoples\u2019 Friendship University of Russia (RUDN)","place":["Moscow, Russian Federation"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2179-3508","authenticated-orcid":false,"given":"Sergei A.","family":"Evteev","sequence":"additional","affiliation":[{"name":"P. Hertsen Moscow Oncology Research Institute","place":["Moscow, Russian Federation"]},{"name":"The Federal State Unitary Enterprise Dukhov Automatics Research Institute","place":["Moscow, Russian Federation"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7884-8579","authenticated-orcid":false,"given":"Sergey Z.","family":"Vatsadze","sequence":"additional","affiliation":[{"name":"N.D. Zelinsky Institute of Organic Chemistry","place":["Moscow, Russian Federation"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8731-6934","authenticated-orcid":false,"given":"Aleksei V.","family":"Medved\u2019ko","sequence":"additional","affiliation":[{"name":"N.D. Zelinsky Institute of Organic Chemistry","place":["Moscow, Russian Federation"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9755-1164","authenticated-orcid":false,"given":"Petr V.","family":"Shegai","sequence":"additional","affiliation":[{"name":"P. Hertsen Moscow Oncology Research Institute","place":["Moscow, Russian Federation"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8784-8415","authenticated-orcid":false,"given":"Andrey D.","family":"Kaprin","sequence":"additional","affiliation":[{"name":"P. Hertsen Moscow Oncology Research Institute","place":["Moscow, Russian Federation"]},{"name":"Peoples\u2019 Friendship University of Russia (RUDN)","place":["Moscow, Russian Federation"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a012559"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/em.22087"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.002"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cotox.2017.10.009"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08467"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114109"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051619"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2021.1866540"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2022.2027911"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.16931"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sbi.2023.102651"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(03)00033-3"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-0004(00)01563-2"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.04.014"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00291"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-0761"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4400874"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature01368"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2011.05.013"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes12050727"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-20-0448"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12912"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2021.09.008"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-016-3869-x"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1239"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1122"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2018-4909"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-17-A094"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa238"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c02277"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1699"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-022-01216-8"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0934"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-CT171"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-CT063"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-23-0890"},{"key":"e_1_3_5_39_1","unstructured":"Zhong W. Substituted 1-(3 3-difluoropiperidin-4-yl)-imidazo[4 5-c]quinolin-2-one compounds with blood-brain barrier penetrable capability. WO2022060377. 2024."},{"key":"e_1_3_5_40_1","unstructured":"Search Orphan Drug Designations and Approvals. [cited 2024 Aug 26]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=924022"},{"key":"e_1_3_5_41_1","unstructured":"CAS SciFinder Discovery Platform. [cited 2024 Aug 26]. Available from: www.cas.org"},{"key":"e_1_3_5_42_1","unstructured":"Cortellis Drug Discovery Intelligence Database. 2024 [cited 2024 Aug 26]. Available from: https:\/\/clarivate.com\/products\/cortellis-family\/"},{"key":"e_1_3_5_43_1","unstructured":"Espacenet. [cited 2024 Aug 26]. Available from: https:\/\/worldwide.espacenet.com\/"},{"key":"e_1_3_5_44_1","unstructured":"Kudos Pharmaceuticals Ltd. Pyranones useful as ATM inhibitors. WO2003070726. 2003."},{"key":"e_1_3_5_45_1","doi-asserted-by":"crossref","unstructured":"Kudos Pharmaceuticals Ltd. Aminopyrones and their use as ATM inhibitors. WO2005016919. 2005.","DOI":"10.3833\/pdr.v2005i58.700"},{"key":"e_1_3_5_46_1","unstructured":"Kudos Pharmaceuticals Ltd. ATM inhibitors. US20060178361. 2006."},{"key":"e_1_3_5_47_1","unstructured":"Kudos Pharmaceuticals Ltd. ATM inhibitor. US2007049588. 2007."},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-021-00654-x"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01819"},{"key":"e_1_3_5_50_1","unstructured":"Fujifilm Corp. Morpholine derivative or salt thereof. WO2015030057. 2017."},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00114"},{"key":"e_1_3_5_52_1","unstructured":"CHDI Foundation Inc. ATM kinase inhibitors and compositions and methods of use thereof. WO2021113506. 2021."},{"key":"e_1_3_5_53_1","unstructured":"CGK Co. Ltd. ATM and ATR inhibitor. WO2007015632. 2007."},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio800"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio0708-431"},{"key":"e_1_3_5_56_1","unstructured":"Novartis Ag. Pyrazolopyrimidines as PI3K lipid kinase inhibitors. WO2008037477. 2008."},{"key":"e_1_3_5_57_1","unstructured":"University Of Basel. Spirocyclic compounds and their use as therapeutic agents and diagnostic probes. WO2011114275. 2011."},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01092"},{"key":"e_1_3_5_59_1","unstructured":"Samsung Electronics Co Ltd. Composition including ATM inhibitor for reducing cellular senescence and use of the composition. US2016113935. 2015."},{"key":"e_1_3_5_60_1","unstructured":"Astrazeneca Ab. Quinoline-3-carboxamide compounds and their use in treating cancer. WO2017162611. 2017."},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b00519"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22920"},{"key":"e_1_3_5_63_1","unstructured":"Pike KG Barlaam B. Cinnolin-4-amine compounds and their use in treating cancer. WO2017162605. 2017."},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0975"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b01896"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00875"},{"key":"e_1_3_5_67_1","unstructured":"Astrazeneca Ab Astrazeneca UK Limited. Imidazo[4 5-c]quinolin-2-one compounds and their use in treating cancer. WO2015170081. 2015."},{"key":"e_1_3_5_68_1","unstructured":"Astrazeneca Ab. N n-dimethyl-3-[5-(3-methyl-2-oxo-1-tetrahydropyran-4-yl-imidazo[4 5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine oxide as ATM (ataxia telangiectasia mutated) kinase modulator for treating cancer. WO2017174446. 2017."},{"key":"e_1_3_5_69_1","unstructured":"Astrazeneca Ab. Imidazo[4 5-c]quinolin-2-one compounds and their use in treating cancer. WO2017076898. 2017."},{"key":"e_1_3_5_70_1","unstructured":"Astrazeneca Ab. Deuterated imidazo[4 5-c]quinolin-2-one compounds and their use in treating cancer. WO2018167203. 2018."},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.11.6.19576"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aat1719"},{"key":"e_1_3_5_73_1","unstructured":"Astrazeneca Ab. 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4 5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (ATM) kinase for the treatment of cancer. WO2017046216. 2017."},{"key":"e_1_3_5_74_1","unstructured":"Astrazeneca Ab. 1 3-dihydroimidazo [4 5-c]cinnolin-2-one compounds and their use in the treatment of cancer. WO2019057757. 2019."},{"key":"e_1_3_5_75_1","unstructured":"IMPACT Therapeutics Inc. Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof. WO2018127195. 2020."},{"key":"e_1_3_5_76_1","unstructured":"IMPACT Therapeutics Inc. Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof. WO2018153365. 2023."},{"key":"e_1_3_5_77_1","unstructured":"IMPACT Therapeutics Inc. Substituted pyrazoloquinazolinone compounds and application thereof. WO2021004482. 2022."},{"key":"e_1_3_5_78_1","unstructured":"IMPACT Therapeutics Inc. Substituted imidazoquinoxaline compounds and uses thereof. WO2021047646. 2021."},{"key":"e_1_3_5_79_1","unstructured":"XRad Therapeutics Inc. Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy. WO2019201283. 2019."},{"key":"e_1_3_5_80_1","unstructured":"XRad Therapeutics Inc. Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy. WO2021022078. 2020."},{"key":"e_1_3_5_81_1","unstructured":"Suzhou Zanrong Pharma Limited. 1-isopropyl-3-methyl-8-(pyridin-3-yl)-1 3-dihydro-2h-imidazo[4 5-c]cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (ATM) kinase and uses thereof. WO2020052688. 2020."},{"key":"e_1_3_5_82_1","unstructured":"Suzhou Zanrong Pharma Limited. Selective modulators of ataxia telangiectasia mutated (ATM) kinase and uses thereof. WO2022194138. 2022."},{"key":"e_1_3_5_83_1","unstructured":"Medshine Discovery Inc. Quinolino-pyrrolidin-2-one derivative and application thereof. WO2020063855. 2022."},{"key":"e_1_3_5_84_1","unstructured":"Medshine Discovery Inc. Substituted quinolinopyrrolidone compound as atm inhibitor and application thereof. WO2021098734. 2021."},{"key":"e_1_3_5_85_1","unstructured":"Medshine Discovery Inc. Quinoline imidazole compound and application thereof. WO2021139814. 2021."},{"key":"e_1_3_5_86_1","unstructured":"CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd. A class of fused ring compounds and preparation and use thereof. WO2022063303. 2024."},{"key":"e_1_3_5_87_1","unstructured":"CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd. Alkyne compound and preparation and application thereof. CN115232122. 2022."},{"key":"e_1_3_5_88_1","unstructured":"CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd. Heterocyclic compound and preparation method and application thereof. CN115304598. 2022."},{"key":"e_1_3_5_89_1","unstructured":"Deutsches Krebsforschungszentrum DKFZ Eberhard Karls Universitaet Tuebingen. Imidazo[4 5-c]quinoline compounds and their use as ATM kinase inhibitors. EP3992191. 2022."},{"key":"e_1_3_5_90_1","unstructured":"Chia Tai Tianqing Pharmaceutical Group Co Ltd Nanjing Shunxin Pharmaceutical Co Ltd. Sulfonyl-containing compounds. CN116496299. 2023."},{"key":"e_1_3_5_91_1","unstructured":"Chia Tai Tianqing Pharmaceutical Group Co Ltd. Hydrazino group-containing compound. WO2023143282. 2023."},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c00082"},{"key":"e_1_3_5_93_1","unstructured":"Sichuan University. 6-pyridine-3-quinoxaline urea derivative and application thereof. CN116535389. 2023."},{"key":"e_1_3_5_94_1","unstructured":"Merck Patent Gmbh. Imidazo [4 5-c]chinoline als DNA-PK-inhibitoren. WO2012028233. 2012."},{"key":"e_1_3_5_95_1","unstructured":"Merck Patent Gmbh. Imidazolonylchinoline und deren verwendung als ATM kinase inhibitoren. WO2016155884. 2016."},{"key":"e_1_3_5_96_1","unstructured":"Merck Patent Gmbh. Imidazolonylquinoline compounds and therapeutic uses thereof. WO2020193660. 2020."},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2019-3500"},{"key":"e_1_3_5_98_1","unstructured":"Yaokang Zhongtuo Jiangsu Pharmaceutical Technology Co ltd. Quinolinoimidazolidone deuterated pyrazole compound and application thereof. CN115716829. 2023."},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab196.309"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-3305"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.01.052"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202302494"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2212072120"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-023-1053-3"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.04.015"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2024.2446228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T04:06:32Z","timestamp":1738382792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2024.2446228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":103,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1080\/13543776.2024.2446228"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2024.2446228","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-09-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}